Globus Medical stock hits 52-week low at 51.79 USD

Globus Medical (NYSE:GMED) Inc. stock has reached a new 52-week low, hitting a price of 51.79 USD. This milestone reflects a challenging period for the company, with the stock down 43.24% over the past six months. According to InvestingPro analysis, despite the decline, the company maintains strong financial health with an overall score of 3.33 out of 5, and analysts see significant upside potential from current levels. The 1-year change data shows a decrease of 24.3%, indicating a substantial drop in value. This downturn comes amid broader market fluctuations and specific challenges within the medical technology sector, affecting investor sentiment and the company’s market performance. InvestingPro data suggests the stock is currently trading below its Fair Value, with strong fundamentals including a healthy current ratio of 4.45 and minimal debt levels. For deeper insights into Globus Medical’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Globus Medical reported preliminary second-quarter revenue of $745 million, surpassing consensus estimates of $740 million. However, the base business results of $651 million fell short of the $664 million consensus expectation, despite a 3.3% reported increase. The company also announced the appointment of Keith Pfeil as the new President and CEO, following the resignation of Daniel Scavilla. Scavilla, who previously led Globus Medical, has now been named the CEO of Dentsply Sirona, effective August 1, 2025. Additionally, Globus Medical expanded its Excelsius navigation capabilities with the introduction of the DuraPro oscillating system, aimed at enhancing spine surgery procedures. In the realm of analyst ratings, Needham maintained its Hold rating on Globus Medical, while Piper Sandler reiterated an Overweight rating with an $80.00 price target. Piper Sandler’s assessment comes despite Globus Medical’s shares struggling in the medical device sector this year. These developments highlight the ongoing changes and strategic initiatives within Globus Medical.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.